Effects of Enhanced External Counter-Pulsation therapy on QT Dispersion in Patients with Heart Failure

Vahid Ghasem Amoeeian1, Kaveh Hosseini1, Ali Bozorgi1, Ehsan Rashidi1, Maryam Shahali Ramshe4, Farzad Masoudkabir4, Mehdi Bayati2, Ali Vasheghani-Farahani8

Abstract

Background: Enhanced External Counter Pulsation (EECP) is a FDA approved non-invasive technique that reduces symptoms of certain heart related diseases in patients. It simulates exercise training condition for patients unable to intercept an actual training session. It also hypothetically affects ECG markers such as QT dispersion in the same way that exercise training does.

Present study is mainly focused on evaluating several ECG parameters including PR, QRS and QT interval before and after using EECP in CHF patients in order to ultimately investigate the impression of EECP on dropping the risk of developing arrhythmias.

Methods: Participants of this cross-sectional study was consist of 26 patients (21 men vs. 5 women) who had indication for EECP, fulfilled the entrance criteria, and were suffering from functional class II or III in NYHA classification and left ventricular Ejection Fraction (EF) ≤ 35 %. Mean age of subjects was 56 ± 2.2 years.

All patients underwent at least 4 ECGs (weekly) and 4 weeks of EECP program. Changes in certain ECG parameters including QRS duration as well as PR and QT intervals were assessed during 4 weeks of using EECP technique for each individual. Baseline ECG was compared with 4th week ECG.

Results: No statistically differences were found between mean QRS duration (P = 0.292), mean PR interval (P = 0.82), and mean QT dispersion (P = 0.89) before and after 4 weeks of EECP therapy.

Conclusion: Based on this cross sectional study, 4 weeks of EECP did not have any significantly impact on ECG parameters. However, EECP might improve patient’s functional capacity.

Keywords: Enhanced External Counter-Pulsation (EECP); QT dispersion; Heart failure; PR interval

Introduction

The growing number of patients with symptomatic heart failure, motivates physicians and researchers to expand new therapeutic methods in order to enhance cardiac contractility of the patients and lower their peripheral vascular resistance which results in better LV function[1]. Enhanced External Counter Pulsation (EECP) is a FDA approved noninvasive technique that reduces heart failure and angina pectoris symptoms in patients[2,3]. Reducing myocardial oxygen demand, increasing venous return as well as cardiac output, and improving the endothelial function are considered as different mechanisms in which EECP can enhance the heart efficacy[4,5]

Previous literature have demonstrated that patient’s functional class based on NYHA classification significantly improves by using EECP technique[6]. QT dispersion is a measure of inter-lead QT interval variability in the surface ECG, described by Campbell et al[7]. The QT dispersion which is defined as the difference of maximal and minimal QT interval duration, reflects the regional differences in ventricular recovery time[8,9]. Recent studies have shown that patients with increased QT dispersion are at greater risk for developing ventricular arrhythmias and sudden cardiac death in heart failure and coronary artery disease[10,11]. The study in Nara medical university have

Received date: June 19, 2017
Accepted date: July 28, 2017
Published date: August 04, 2017

Corresponding author:
Ali Vasheghani-Farahani, Assistant professor of cardiology, Cardiac Primary Prevention Research Center (CPPRC), Department of cardiology, Tehran Heart Center, Karegar Shomali St., Jalal al-Ahmad Cross, Tehran, Iran


DOI: 10.15436/2378-6914.17.1577
EECP therapy in heart failure patients

demonstrated the benefits of exercise training on sympathovagal balance which leads to reduced QTd[3]. EECP technique simulates exercise training condition for patients unable to intercept an actual training session and hypothetically affects ECG markers in the same way that exercise training does. Assessing the QT dispersion might be useful in arrhythmia risk assessment and evaluating the effectiveness of antiarrhythmic drug therapy[4]. As a matter of fact, clinical interventions in order to reduce QT dispersion might have a favorable impact on clinical outcomes. The aim of present study is to evaluate several ECG parameters including PR interval, QRS and QT interval, in heart failure group before and after using EECP. Indeed, we aim to investigate the impression of EECP on dropping the risk of developing arrhythmias in CHF patients.

Methods and Material

This cross sectional study was conducted in Tehran Heart Center from May 2015 to August 2016. All participants had symptomatic heart failure despite maximum medical (pharmacological) treatments. Selection method has been depicted in Figure 1.

Mean QRS duration was measured 80.76 milliseconds (ms) before EECP and 82.3ms after EECP sessions. This alteration was not found statistically significant with Wilcoxon method, P value: 0.292, Figure 1.

Figure 1: QRS duration (milliseconds) before and after EECP.

Participant Selection

All participants referred from Tehran Heart Center with functional class II or III in NYHA classification and left ventricular Ejection Fraction (EF) ≤ 35 % were included in this study. Exclusion criteria were as follows; severe impairment of cardiac function and to exclude significant valvular disease. In each session 12 lead ECG was done and electrocardiographic parameters such as: QT interval (the duration between the initiation of the Q wave and end of the T wave), QT dispersion (maximum QT interval minus minimum QT interval), QRS duration (A combination of the Q wave, R wave and S wave with normal duration of 0.08 to 0.10 seconds) and PR (measured from the beginning of the P wave to the beginning of the QRS wave) were evaluated before and after EECP.

QT dispersion (QTd) and corrected QT dispersion (QTcd) were measured by two expert cardiologists. Corrected QT dispersion was calculated by Bazett formula. In case of disagreement on measured QTd, a third cardiologist was involved.

EECP technique

EECP is done by a technician under the supervision of a cardiologist for duration of one-hour per day in a total of 35 sessions over 7 weeks. The EECP device is consist of three pneumatic cuffs applied to the calves, lower thighs, and upper thighs. A computer-controlled pneumatic system inflates the cuffs in sequence at initiation of diastole, generating approximately 300 mm Hg of external pressure. At the onset of systole, the external pressure is released and causes a decline in systolic pressure. Inflation process starts by the electrocardiographic R-wave and continues until the induced retrograde pulse wave improves the cardiac output. For monitoring the pulse pressure wave form, a finger plethysmogram is involved.

Statistical Analysis

All data were analyzed with SPSS software version 23.0 for Windows (SPSS, Chicago, IL, USA). Evaluation of the normality was done with Kolmogorov–Smirnov test. Normal Variables were analyzed with paired T-test and in case of significant difference from normal distribution, Wilcoxon method was used. P values < 0.05 were considered significant.

Results

Demographic characteristics of 26 patients who were participated in current study are shown in Table 1.

Mean age of subjects was 56 ± 2.2 years. Male dominance was evident (21 men vs. 5 women). Changes of certain ECG parameters including PR interval, QRS duration, and QT interval were assessed during 4 weeks of using EECP technique.
EECP therapy in heart failure patients

for each individual. Baseline ECG was compared with 4th week ECG.

Table 1: Patient Demographics and Baseline Characteristics (n = 26).

<table>
<thead>
<tr>
<th>Patients Characteristics</th>
<th>Percentage or Mean</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>56 ± 2.2</td>
</tr>
<tr>
<td>Gender</td>
<td>22 (84%) Male</td>
</tr>
<tr>
<td></td>
<td>4 (16%) Female</td>
</tr>
<tr>
<td>Hypertension</td>
<td>25 (96%)</td>
</tr>
<tr>
<td>Diabetes Mellitus</td>
<td>14 (54%)</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>24 (92%)</td>
</tr>
<tr>
<td>Current Smoking</td>
<td>6 (23%)</td>
</tr>
<tr>
<td>Prior smoking</td>
<td>23 (88%)</td>
</tr>
<tr>
<td>Left Ventricular Ejection Fraction</td>
<td>30%</td>
</tr>
</tbody>
</table>

Mean PR interval was measured 189.6ms before EECP and 190.7ms after EECP sessions. This alteration was also not found statistically significant, analyzed with paired T test, P value: 0.82, Figure 2.

Figure 2: PR interval (milliseconds) before and after EECP.

Most importantly, the differences between mean QT dispersion before and after EECP were measured 65.7ms and 64.4ms respectively and were compared to each other with T test. The difference was not statistically significant. (P value: 0.89) Figure 3

![Figure 3: QT dispersion (milliseconds) before and after EECP.](image)

Discussion

According to statistics, 550,000 new cases of HF are reported annually in U.S.\(^{[13]}\). Total financial expenses related to HF was estimated around $27.9 billion plus another $2.9 billion annually for its treatments\(^{[13]}\). Based on previous researches, EECP technique accounts to be an effective rehabilitation method for patients suffering from HF and poor functional class. Soran O et al have reported EECP technique to be safe and without any harmful effects during treatment\(^{[16]}\). Prospective cohort studies in 2012 on 68 patients have shown that EECP rehabilitation causes significant enhancements in functional class (p < 0.001) and LVEF (p < 0.001)\(^{[15]}\). In a remarkable study, a large number of patients participated in International EECP Patient Registry were evaluated. Results demonstrate that EECP therapy is a safe and effective treatment for patients with angina or severe LVD who could not undergo CABG or PCI\(^{[16]}\). EECP has also positive effects on refractory angina pectoris and quality of life. An interesting review article on this subject was published in 2007 by Manchanda A et al. They investigated the previous articles on effects of using EECP for treatment of angina pectoris\(^{[17]}\). One of the major advantages of using EECP is that this technique can enhance the patient’s quality of life in various ways which was observed during our study and confirmed by other papers\(^{[16]}\). The International Index of Erectile Function (IIEF) scores was compared pre- and post-EECP therapy in a cohort with 120 participants. Results show a significant improvement in erectile function (p = 0.003)\(^{[18]}\). Campbell et al (2008) have revealed the various effects of EECP technique on brachial blood pressure of patients with normal, low, and high systolic blood pressure. It is declared that EECP technique causes a rise in both systolic and diastolic BP in patients with low BP. On the contrary, it decreases the systolic BP as well as diastolic BP in normal or hypertensive patients\(^{[19]}\). Another study by Nichols et al (2006) on patients with refractory angina have shown that EECP treatment results in a major reduction in both peripheral and central systolic pressure along with pulse pressure\(^{[20]}\). Different effects of EECP on cardiovascular system are briefed in table 2.

Table 2: Effects of EECP therapy.

<table>
<thead>
<tr>
<th>Effect Changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac after load</td>
</tr>
<tr>
<td>Cardiac Oxygen use</td>
</tr>
<tr>
<td>Coronary flow</td>
</tr>
<tr>
<td>Endothelial function</td>
</tr>
<tr>
<td>Vasodilatation</td>
</tr>
<tr>
<td>Collateral arteries</td>
</tr>
<tr>
<td>Arteries perfusion</td>
</tr>
<tr>
<td>Ischemia in heart and other organs</td>
</tr>
</tbody>
</table>

Two different studies on effects of EECP on ECG parameters have shown similar results. Akbarzadeh F. et al (2011) have measured QRS duration, PR interval, QT interval, and QTc interval. Mean QRS duration was declared decreased at the end of study (108 ± 18 ms before and 105 ± 17 ms after EECP). QT interval was also reported decreased (from 396 ± 22 ms to 391 ± 24 ms). QTc interval was changed from 402 ± 22 ms to 399 ± 22 ms. But PR interval showed a rise. All of these changes were reported statistically insignificant\(^{[21]}\). Another work by Henrikson CA et al (2004) was also devoted to measuring the same ECG parameters as mentioned. They have announced that there was no statistically significant changes in assessed markers\(^{[22]}\). One of the variables that may have a significant impact on outcome of heart failure patients after different interventions is metabolic syndrome\(^{[22,24]}\). In current study, there only available the data was related to blood pressure and diabetes which was not correlated to outcome of patients. However, diabetes may influence the prognosis of heart failure patients with ICDs and CRT-d\(^{[25]}\). Comparison between other parameters of metabolic syndrome and patient outcomes or ECG alterations is recommended for future investigations.
EECP therapy in heart failure patients

Conclusion: Based on this cross sectional study, EECP did not significantly reduced QT dispersion. However, EECP might improve functional capacity. The effects of EECP on ECG markers have not been yet proven. This may reflect the fact that EECP improves the quality of life in heart failure patients but have no positive influence on prognosis of the disease. We recommend a similar multicenter study with expanded number of participants.

Conflict of Interest: None declared.

Limitations: This is a single center open label non-randomized trial with no control or placebo group study. Drug changes were not monitored during the trial. Most of the participants did not complete 35 sessions. Small sample size is another limitation of current work. We recommend multicenter approach with a larger sample size for future investigations. Not all of the items related to metabolic syndrome, which may affect the outcome of the patients, were included in our collected data. 6 and 12 month follow-up of patients for the number of hospital admissions, functional class changes, and ECG parameters alterations is recommended for future studies.

Acknowledgements: The authors would like to thank Students’ Scientific Research Center (SSRC) and Cardiac Primary Prevention Research Center for their support and the Research Development Center of Tehran Heart Center for their technical assistance. This study is supported in all aspects by Tehran University of Medical Sciences (TUMS).

References


